# IPSOS (NCT03191786)

> A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03191786
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Vinorelbine; Gemcitabine
- Enrollment: 453
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 21
- YouTube: 10
- Podcasts: 4
- Bluesky threads: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ipsos-nct03191786

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03191786", "email": "<work email>"}; the inbox owner confirms by the emailed link.